First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants

Jul 08 13:07 2019 Print This Article

Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.

The post First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants appeared first on DrugPatentWatch - Make Better Decisions.The post First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants appeared first on Biotechblog.

Read More

About Article Author

Biotech Blog

  Categories:

Related Items

Three reasons to buy Theratechnologies from Mackie Research

Mackie Research analyst André Uddin is staying bullish on specialty pharma company Theratechnologies (Theratechnologies Stock Quote, Chart, News TSX:TH) after its latest quarterly results. The analyst reviewed Theratechnologies fourth quarter in a report to clients on Tuesday and reiterated his †...

Tech Talk for Monday February 24th 2020

Pre-opening Comments for Monday February 24th Equity Index futures were lower this morning. S&P 500 futures were down 85 points to 3,259.25. Index futures responded to concerns that the coronavirus has spread beyond China. Several sectors responded strongly to rising coronavirus concerns. Gold jum ...

Acasti Pharma has price target cut at Echelon

Delays at Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) have Echelon Wealth Partners analyst Douglas Loe lowering his price target on the stock. On Monday, after finding what it said were “some unexpected and inconsistent findings that it believes may have negatively contribute ...

Yikes to the Year End!

Originally published in December 2019 Clearly, there is more going on these days in Washington, D.C. than just the impeachment hearings, and activities this week made that point clear. In the span of only a few days, we saw progress on two key issues – the China 301 tariffs and the U.S.-Mexico-Ca ...

Pfizer’s dividend is safe, this investor says

Is now the time to buy Pfizer (Pfizer Stock Quote, Chart, News NYSE:PFE)? The pharma giant was rallying successfully before it hit a roadblock with its latest quarterly earnings, leaving investors wondering whether this pullback is the event they’ve been looking for. Portfolio manager Paul Harris ...

Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares

Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares Original press release here BURNABY, British Columbia, Jan. 27, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing ...

HLS Therapeutics gets yet another price target raise at Stifel Canada

Stifel Canada analyst Justin Keywood has raised his target price on specialty pharma company HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News TSX:HLS) based on a new de-risking event for the stock. Namely, the Canadian launch of cardiovascular drug Vascepa. In an update to clients on Tue ...

Bloom Burton & Co. Announces the 2020 Bloom Burton Award Gala

Bloom Burton & Co. Announces the 2020 Bloom Burton Award Gala Annual Award Recognizes the Most Significant Contributor to Canada’s Innovative Healthcare Industry Original press release here January 28, 2020 07:30 AM Eastern Standard Time TORONTO–(BUSINESS WIRE)–Bloom Burton & Co. (“Bloom Bu ...

Tech Talk for Tuesday January 28th 2020

Pre-opening Comments for Tuesday January 28th U.S. equity index futures were higher this morning. S&P 500 futures were up 21 points in pre-opening trade. Index futures were virtually unchanged following release of December Durable Goods Orders at 8:30 AM EST. Consensus was an increase of 0.3% versu ...

The Ten Best Performing Canadian Life Sciences Stocks of 2019

It was another up and down year for Canadian Life Sciences stocks. In 2018, the downfall of the sector came in the last couple of months. A year later, it happened early when cannabis stocks began to collapse. (The S&P TSX Pharma & Biotech Index lost almost half of its value between March and the [ ...